Early‑onset colorectal cancer: A distinct entity with unique genetic features

Jiang,Dan; Shu,Chang; Lei,Chuanfen; Wan,Ying; Sun,Linyong

doi:10.3892/ol.2020.11894

Early‑onset colorectal cancer: A distinct entity with unique genetic features

Authors:
- Dan Jiang
- Chang Shu
- Chuanfen Lei
- Ying Wan
- Linyong Sun
View Affiliations

Affiliations: Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Chengdu, Sichuan 610041, P.R. China
Published online on: July 17, 2020 https://doi.org/10.3892/ol.2020.11894
Article Number: 33
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to elucidate the genetic features of early‑onset colorectal cancer (CRC), particularly the genetic mutations that may be regarded as prognostic and/or predictive markers in CRC and other malignancies. In total, 40 patients with non‑polyposis CRC aged 35 or younger were selected. The formalin‑fixed, paraffin‑embedded tumors acquired were subjected to mismatch repair (MMR) protein immunochemical staining and gene analysis with next‑generation sequencing (44 exons, 17 genes; Ion Torrent Sequencing Platform). A total of 11 (27.5%) tumors presented with MMR protein deficiency (dMMR) and 26 (65%) tumors harbored one or more genetic mutations, including K‑RAS proto‑oncogene (35%), phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit alpha (PIK3CA; 20%), B‑Raf proto‑oncogene (5%), erb‑b2 receptor tyrosine kinase 2 (5%), discoidin domain receptor tyrosine kinase 2 (5%), N‑RAS proto‑oncogene (2.5%), KIT proto‑oncogene (2.5%), TSC complex subunit 1 (2.5%), DNA methyltransferase 3 alpha (2.5%) and ABL proto‑oncogene 1 (2.5%). Of the dMMR tumors, 81.8% (9/11) of cases presented with mutations in the tested genes, while only 58.6% (17/29) of the MMR‑proficient (pMMR) tumors presented with these (P=0.158). PI3KCA was frequently mutated in dMMR tumors compared to pMMR tumors (P=0.025). In a subgroup with a family history of CRC, the dMMR status (P<0.001) and PIK3CA genetic mutation status (P=0.01) were more frequently observed compared to the other two groups (with a family history of other cancer types or no malignancy). Almost all patients who had relatives with CRC presented with both dMMR and other genetic mutations, while this was not observed in the patients who had relatives with other types of carcinoma. Certain genetic mutations that are rarely reported in CRC were only identified in those patients with a family history of carcinoma. In conclusion, non‑polyposis CRC in young adults presents as a distinct entity with a unique set of genetic features. However, investigation of more cases in further studies is required to verify the present results.

View Figures

View References

1	Stigliano V, Sanchez-Mete L, Martayan A and Anti M: Early-onset colorectal cancer: A sporadic or inherited disease? World J Gastroenterol. 20:12420–12430. 2014. View Article : Google Scholar : PubMed/NCBI
2	Singh KE, Taylor TH, Pan CG, Stamos MJ and Zell JA: Colorectal cancer incidence among young adults in California. J Adolesc Young Adult Oncol. 3:176–184. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, Cantor SB and Chang GJ: Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg. 150:17–22. 2015. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics, 2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
5	Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellisé M, Esteban L, Kaminski MF, et al: Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 68:1820–1826. 2019. View Article : Google Scholar : PubMed/NCBI
6	Al-Barrak J and Gill S: Presentation and outcomes of patients aged 30 years and younger with colorectal cancer: A 20-year retrospective review. Med Oncol. 28:1058–1061. 2011. View Article : Google Scholar : PubMed/NCBI
7	Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA and Vilar E: High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 33:3544–3549. 2015. View Article : Google Scholar : PubMed/NCBI
8	Siegel RL, Jakubowski CD, Fedewa SA, Davis A and Azad NS: Colorectal Cancer in the Young: Epidemiology, prevention, management. Am Soc Clin Oncol Educ Book. 40:1–14. 2020.PubMed/NCBI
9	Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF and Chen YT: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol. 33:572–582. 2009. View Article : Google Scholar : PubMed/NCBI
10	Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ and Wolf CR: Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA. 99:9433–9438. 2002. View Article : Google Scholar : PubMed/NCBI
11	Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
12	Okugawa Y, Grady WM and Goel A: Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 149:1204–1225 e12. 2015. View Article : Google Scholar : PubMed/NCBI
13	Peltomaki P and de la Chapelle A: Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res. 71:93–119. 1997. View Article : Google Scholar : PubMed/NCBI
14	Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A and Pritchard CC: Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 147:1308–1316 e1. 2014. View Article : Google Scholar : PubMed/NCBI
15	National Comprehensive Cancer Network, . Colon cancer treatment guidelines. October 19–2018
16	National Comprehensive Cancer Network, . Rectal cancer treatment guidelines. August 7–2018
17	Shaw AT and Engelman JA: ALK in lung cancer: Past, present, and future. J Clin Oncol. 31:1105–1111. 2013. View Article : Google Scholar : PubMed/NCBI
18	Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Paya A, Brea A, Egoavil CM, Castillejo A, Barbera VM, Bessa X, et al: Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 61:865–872. 2012. View Article : Google Scholar : PubMed/NCBI
19	Xu Z, Huo X, Ye H, Tang C, Nandakumar V, Lou F, Zhang D, Dong H, Sun H, Jiang S, et al: Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform. PLoS One. 9:e1004422014. View Article : Google Scholar : PubMed/NCBI
20	Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, et al: Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: An adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 25:1128–1139. 2012. View Article : Google Scholar : PubMed/NCBI
22	O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH and Ko CY: Do young colon cancer patients have worse outcomes? World J Surg. 28:558–562. 2004. View Article : Google Scholar : PubMed/NCBI
23	Ballester V, Rashtak S and Boardman L: Clinical and molecular features of young-onset colorectal cancer. World J Gastroenterol. 22:1736–1744. 2016. View Article : Google Scholar : PubMed/NCBI
24	Li SKH and Martin A: Mismatch repair and colon cancer: Mechanisms and therapies explored. Trends Mol Med. 22:274–289. 2016. View Article : Google Scholar : PubMed/NCBI
25	Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
26	Shen Y, Wang J, Han X, Yang H, Wang S, Lin D and Shi Y: Effectors of epidermal growth factor receptor pathway: The genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One. 8:e816282013. View Article : Google Scholar : PubMed/NCBI
27	Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
28	Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 363:2424–2433. 2010. View Article : Google Scholar : PubMed/NCBI
30	Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, et al: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 43:309–315. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kim MS, Kim YR, Yoo NJ and Lee SH: Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers. APMIS. 121:85–94. 2013. View Article : Google Scholar : PubMed/NCBI
32	Li WL, Xiao MS, Zhang DF, Yu D, Yang RX, Li XY and Yao YG: Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer. Gene. 546:263–270. 2014. View Article : Google Scholar : PubMed/NCBI
33	Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
34	Al-Shamsi HO, Alhazzani W and Wolff RA: Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. J Gastrointest Oncol. 6:314–321. 2015.PubMed/NCBI
35	Chou CL, Chang SC, Lin TC, Chen WS, Jiang JK, Wang HS, Yang SH, Liang WY and Lin JK: Differences in clinicopathological characteristics of colorectal cancer between younger and elderly patients: An analysis of 322 patients from a single institution. Am J Surg. 202:574–582. 2011. View Article : Google Scholar : PubMed/NCBI
36	Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, et al: Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res. 74:7217–7228. 2014. View Article : Google Scholar : PubMed/NCBI
37	Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
38	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Muller MC, Ernst T, Rosti G, et al: BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European Leukemia Net. Blood. 118:1208–1215. 2011. View Article : Google Scholar : PubMed/NCBI
39	McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB and McAlpine JN: Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 137:306–310. 2015. View Article : Google Scholar : PubMed/NCBI